- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Belzutifan Plus Pembrolizumab and Lenvatinib Demonstrates Potential in Advanced Clear Cell RCC
October 18th 2025, 12:55pm
Belzutifan plus pembrolizumab and lenvatinib improved efficacy outcomes compared with multiple other pembrolizumab-based triplet regimens in advanced clear cell renal cell carcinoma.
RNA Sequencing Signatures May Guide Treatment Selection in Advanced ccRCC
October 18th 2025, 11:33am
RNAseq-defined clusters guided treatment selection in metastatic ccRCC in the phase 2 OPTIC trial, yielding a 76% ORR with cabozantinib plus nivolumab.
Fruquintinib Plus Sintilimab Improves PFS in Advanced RCC After First-Line VEGFR TKI Therapy
October 18th 2025, 1:59am
Fruquintinib plus sintilimab significantly extended progression-free survival in advanced RCC following first-line VEGFR TKI therapy.
Long-Term MANEUVER Trial Data Spotlight Durable Responses With Pimicotinib in TGCT
October 17th 2025, 11:20pm
Long-term data demonstrated durable responses with pimicotinib in tenosynovial giant cell tumor.
Regorafenib Plus Nivolumab Yields Nonsuperior Survival in Refractory Gastric/GEJ Cancer
October 17th 2025, 9:21pm
regorafenib/nivolumab may encourage a search for more non-chemotherapy combinations for gastric cancer.
Osimertinib Plus Chemo Demonstrates OS Benefit in EGFR+ NSCLC With Poor Prognostic Factors
October 17th 2025, 8:40pm
Osimertinib plus chemotherapy improved OS vs osimertinib alone in EGFR-mutated advanced non–small lung cancer, irrespective of poor prognostic factors.
SunRISe-4 Data Support Role for Neoadjuvant Gemcitabine Intravesical System Plus Cetrelimab in MIBC
October 17th 2025, 8:33pm
SunRISe-4 data show that TAR-200 and cetrelimab led to a high pCR and 12-month RFS rate in muscle-invasive bladder cancer.
Osimertinib Plus Local Consolidative Therapy Significantly Extends PFS in EGFR-Mutant NSCLC
October 17th 2025, 8:08pm
NorthStar findings support osimertinib plus local consolidative therapy in EGFR-mutant non–small cell lung cancer.
Adjuvant Ribociclib Plus AI Therapy Has Long-Term Activity in HR+, HER2-Negative Early Breast Cancer
October 17th 2025, 8:05pm
Adjuvant ribociclib plus an aromatase inhibitor was safe and displayed long-term efficacy in hormone receptor–positive, HER2-negative early breast cancer.
Durvalumab Plus FLOT Prolongs OS vs FLOT Alone in Gastric/GEJ Adenocarcinoma
October 17th 2025, 7:25pm
The addition of durvalumab to FLOT prolonged overall survival vs FLOT alone in resectable gastric/gastroesophageal junction adenocarcinoma.
Sevabertinib Yields Robust Responses in HER2-Mutant Advanced NSCLC
October 17th 2025, 6:55pm
Sevabertinib monotherapy led to robust and durable responses in first-line and pretreated patients with HER2-mutant advanced non–small cell lung cancer.
Abemaciclib Plus Endocrine Therapy Provides OS Benefit in HR+/HER2-Negative Breast Cancer
October 17th 2025, 6:36pm
The addition of adjuvant abemaciclib to endocrine therapy provided an OS benefit vs endocrine therapy alone in hormone receptor–positive breast cancer.
First-Line Alectinib Yields Clinically Meaningful OS Benefit in Advanced ALK+ NSCLC
October 17th 2025, 6:31pm
First-line alectinib produced a clinically meaningful overall survival benefit in advanced ALK-positive non–small cell lung cancer.
Combining Durvalumab With BCG Yields Significant DFS Benefit vs BCG Alone in BCG-Naive NMIBC
October 17th 2025, 6:23pm
Durvalumab plus BCG induction and maintenance therapy yielded clinically meaningful improvement in DFS vs BCG induction and maintenance therapy alone in BCG-naive, high-risk NMIBC.
Zongertinib Displays Activity in Frontline HER2-Mutated NSCLC
October 17th 2025, 5:49pm
Zongertinib was effective for the first-line treatment of patients with treatment-naive HER2-mutated NSCLC.
Lenvatinib Plus Pembrolizumab and Chemotherapy Fails to Improve OS in Advanced ESCC
October 17th 2025, 5:23pm
First-line treatment with lenvatinib, pembrolizumab, and chemotherapy did not improve OS vs chemoimmunotherapy in patients with advanced ESCC.
Dr Necchi on Biomarker Data From the SunRISe-4 Trial of Gemcitabine Intravesical System Plus Cetrelimab in MIBC
October 17th 2025, 5:20pm
Andrea Necchi, MD, discusses the role of minimal residual disease assessment in the phase 2 SunRISe-4 trial evaluating TAR-200 plus cetrelimab in MIBC.
Dr Mok on Final OS Data From the ALEX Study Evaluating First-Line Alectinib in ALK+ NSCLC
October 17th 2025, 5:14pm
Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO, shares final OS data from the phase 3 ALEX study in ALK-positive NSCLC.
Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resected MIUC
October 17th 2025, 3:07pm
Five year follow up results from CheckMate 274 support adjuvant nivolumab as a standard of care for high-risk muscle-invasive urothelial carcinoma.
Dr Perol on Unmet Need for Post Immunotherapy Strategies in Lung Cancer
October 16th 2025, 3:20pm
Bridging the Gaps in Lung Cancer
Maurice Perol, MD, discusses the persistent unmet need for effective treatments following progression on immunotherapy in NSCLC.